Biocon Biologics Gets USFDA Approval for Cancer Biosimilar Jobevne
Published • 10 April 2025 at 3:03 PM
USFDA Approves Biocon's Jobevne Biosimilar for Cancer Treatment
Biocon Biologics, a subsidiary of Biocon Ltd, has received approval from the US Food and Drug Administration (USFDA) to market Jobevne (bevacizumab-nwgd), a biosimilar to the cancer drug Avastin. Jobevne, a recombinant humanised monoclonal antibody, is used to treat various types of cancer by inhibiting vascular endothelial growth factor (VEGF) and preventing angiogenesis, which limits tumor growth. This approval marks a significant achievement for Biocon Biologics, as Jobevne becomes their seventh biosimilar approved in the US. The company already markets the drug under the brand name Abeymy in Europe and Canada. Biocon Biologics’ CEO, Shreehas Tambe, emphasized that this approval reinforces the company’s commitment to providing high-quality, affordable cancer treatments, enhancing access to oncology care globally.
USFDA Greenlights Biocon Biologics’ Jobevne Cancer Drug
- Biocon Biologics receives USFDA approval for Jobevne (bevacizumab-nwgd).
- Jobevne is a biosimilar to the cancer drug Avastin.
- The drug is a recombinant humanized monoclonal antibody used in cancer treatment.
- Jobevne inhibits vascular endothelial growth factor (VEGF) to limit tumor growth by preventing angiogenesis.
- It marks Biocon Biologics’ seventh biosimilar approval in the US.
- The drug is already marketed as Abeymy in Europe and Canada.
- CEO Shreehas Tambe highlights the company's commitment to providing affordable, high-quality cancer treatments.
- The approval strengthens Biocon Biologics' oncology portfolio and enhances global access to cancer care.
